Pfizer Sees Celebrex Script Growth In Days Following Bextra Withdrawal
This article was originally published in The Tan Sheet
Pfizer is seeing an increase in Celebrex prescriptions in the days following the withdrawal of its other COX-2 inhibitor, Bextra, the company said April 19
You may also be interested in...
An FDA decision to request revised safety labeling changes to OTC NSAIDs enables manufacturers to continue positioning the drugs as safer alternatives to their prescription counterparts, which will carry "black box" warnings going forward
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning